Online Inquiry

Hit Identification Services of Radiopharmaceutical Discovery

Following target validation, hit identification marks the first essential step in drug discovery. The quality and characteristics of the hit series significantly influence the likelihood of rapidly progressing into a developable preclinical drug candidate. Rdcthera, a leading CRO in radiopharmaceutical discovery, is here to ensure your success with our integrated hit identification services.

Hit Identification in Radiopharmaceutical Discovery

In the context of radiopharmaceutical discovery, a Hit refers to a compound exhibiting desired biological or chemical activity that potentially leads to the development of a diagnostic or therapeutic agent. Discovery of hits becomes one of the pivotal steps in the drug discovery process that paves the way for the following optimization and development steps.

Fig 1. Drug discovery process.

The Process of Hit Identification

The first step in the drug discovery pipeline is hit identification, where active-profiling compounds are identified and validated. This is carried out using high-throughput screening (HTS), in silico modeling, and other biochemical studies that show which compounds best interact with the target under investigation. At Rdcthera, we are using state-of-the-art technology and methodologies in hit identification in order to assure that only top-of-the-line candidates pass to the next step of development.

Rdcthera Offers Hit Identification Integrated Solutions

Rdcthera is a contract research organization (CRO) providing research solutions for the discovery of new therapeutic agents that address high unmet medical needs. Our integrated hit identification services help to guide and assist in defining an optimal and customized strategy to identify hits for your preferred target.

  • Comprehensive Hit Identification Services

We offer a range of complementary cutting-edge technologies to screen for or design novel hits, including:

  • High-Throughput Screening (HTS)
  • Biochemical Assays
  • DNA-Encoded Libraries
  • AI-Based De Novo Design
  • Biophysics SPR, DSF, ITC, NMR
  • In Silico Screening
  • Radiolabeling
  • Fragment Libraries Screening
  • Computer-assisted Drug Design (CADD)
  • Biophysics SPR, DSF, ITC, NMR

Rdcthera adopts an integrated approach that ensures every project is fitted precisely to the unique needs and objectives of our clients, representing a seamless and effective pathway from hit identification to preclinical development.

  • Custom Hit Identification Solutions

Recognizing that each project is unique, Rdcthera offers customized hit identification solutions to meet specific client needs. Our tailored services include

  • Custom Library Screening

Designing and screening custom compound libraries focused on specific chemical scaffolds or target families.

  • Target-Specific Assays

Developing and optimizing assays tailored to the unique characteristics of the client's target.

  • Collaborative Project Design

Work closely with customers in the design of hit identification strategies that meet the needs and timetable of their research.

Ready to turbocharge your radiopharmaceutical discovery with our cutting-edge hit identification services? Contact Rdcthera today to understand how we can support your research endeavors.

For research use only. Not intended for any clinical use.

Rdcthera RDC

Rdcthera offers efficient, customized, and professional R&D services related to radionuclide drug conjugates.

Copyright © Rdcthera. All rights reserved. Privacy Policy | Cookie Policy